Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.

Allen-Petersen BL, Sears RC.

BioDrugs. 2019 Aug 7. doi: 10.1007/s40259-019-00370-5. [Epub ahead of print] Review.

PMID:
31392631
2.

The use of protein phosphatase 2A activators in combination therapies for pancreas cancer.

Allen-Petersen BL, Sears RC.

Oncotarget. 2019 Mar 12;10(21):2008-2009. doi: 10.18632/oncotarget.26772. eCollection 2019 Mar 12. No abstract available.

3.

A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.

Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, Tumanov S, Allen-Petersen BL, Link J, Kendsersky ND, Vringer E, Schug M, Novo D, Hwang RF, Evans RM, Nixon C, Dorrell C, Morton JP, Norman JC, Sears RC, Kamphorst JJ, Sherman MH.

Cancer Discov. 2019 May;9(5):617-627. doi: 10.1158/2159-8290.CD-18-1212. Epub 2019 Mar 5.

PMID:
30837243
4.

Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting.

Langer EM, Allen-Petersen BL, King SM, Kendsersky ND, Turnidge MA, Kuziel GM, Riggers R, Samatham R, Amery TS, Jacques SL, Sheppard BC, Korkola JE, Muschler JL, Thibault G, Chang YH, Gray JW, Presnell SC, Nguyen DG, Sears RC.

Cell Rep. 2019 Jan 15;26(3):608-623.e6. doi: 10.1016/j.celrep.2018.12.090.

5.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.

PMID:
30389701
6.

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.

Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC.

Nat Commun. 2017 Nov 23;8(1):1728. doi: 10.1038/s41467-017-01967-6.

7.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ, Sears RC.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62. doi: 10.1073/pnas.1317630111. Epub 2014 Jun 9.

8.

Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Allen-Petersen BL, Carter CJ, Ohm AM, Reyland ME.

Oncogene. 2014 Mar 6;33(10):1306-15. doi: 10.1038/onc.2013.59. Epub 2013 Mar 11.

9.

Loss of protein kinase C delta alters mammary gland development and apoptosis.

Allen-Petersen BL, Miller MR, Neville MC, Anderson SM, Nakayama KI, Reyland ME.

Cell Death Dis. 2010;1:e17. doi: 10.1038/cddis.2009.20.

Supplemental Content

Loading ...
Support Center